SG11201912813SA - Plasminogen treatment of conditions associated with pai-1 overexpression - Google Patents
Plasminogen treatment of conditions associated with pai-1 overexpressionInfo
- Publication number
- SG11201912813SA SG11201912813SA SG11201912813SA SG11201912813SA SG11201912813SA SG 11201912813S A SG11201912813S A SG 11201912813SA SG 11201912813S A SG11201912813S A SG 11201912813SA SG 11201912813S A SG11201912813S A SG 11201912813SA SG 11201912813S A SG11201912813S A SG 11201912813SA
- Authority
- SG
- Singapore
- Prior art keywords
- pai
- overexpression
- conditions associated
- plasminogen treatment
- plasminogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523901P | 2017-06-23 | 2017-06-23 | |
| PCT/IB2018/000655 WO2018234861A1 (en) | 2017-06-23 | 2018-06-22 | PLASMINOGEN TREATMENT OF AFFECTIONS ASSOCIATED WITH OVEREXPRESSION OF PAI-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912813SA true SG11201912813SA (en) | 2020-01-30 |
Family
ID=64737041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912813SA SG11201912813SA (en) | 2017-06-23 | 2018-06-22 | Plasminogen treatment of conditions associated with pai-1 overexpression |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11826404B2 (ru) |
| EP (1) | EP3641888B1 (ru) |
| JP (1) | JP2020524689A (ru) |
| KR (1) | KR20200019217A (ru) |
| CN (1) | CN110831668B (ru) |
| AU (1) | AU2018287316A1 (ru) |
| BR (1) | BR112019027229A2 (ru) |
| CA (1) | CA3068153A1 (ru) |
| CL (1) | CL2019003789A1 (ru) |
| DK (1) | DK3641888T3 (ru) |
| ES (1) | ES2965937T3 (ru) |
| FI (1) | FI3641888T3 (ru) |
| IL (1) | IL271470A (ru) |
| MX (1) | MX2019015741A (ru) |
| RU (1) | RU2020100080A (ru) |
| SG (1) | SG11201912813SA (ru) |
| TW (1) | TW201904990A (ru) |
| WO (1) | WO2018234861A1 (ru) |
| ZA (1) | ZA202000280B (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11389515B2 (en) | 2016-12-15 | 2022-07-19 | Talengen International Limited | Method for mitigating heart disease |
| TWI684459B (zh) | 2016-12-15 | 2020-02-11 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療動脈粥樣硬化及其併發症的方法 |
| TW201829448A (zh) | 2016-12-15 | 2018-08-16 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途 |
| CN115427066A (zh) * | 2020-02-06 | 2022-12-02 | 泰伦基国际有限公司 | 一种预防和治疗多发性硬化症的方法和药物 |
| TW202143999A (zh) * | 2020-03-24 | 2021-12-01 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物 |
| TW202144001A (zh) * | 2020-03-24 | 2021-12-01 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療阿茲海默症的方法和藥物 |
| CN115697386A (zh) * | 2020-03-24 | 2023-02-03 | 泰伦基国际有限公司 | 一种治疗帕金森病的方法和药物 |
| CN112174979B (zh) * | 2020-10-27 | 2021-09-07 | 黑龙江中医药大学 | 一种治疗多囊卵巢综合征的药物及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| US6677473B1 (en) * | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
| AU3173301A (en) * | 2000-02-11 | 2001-08-20 | European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
| GB0509438D0 (en) | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| AU2007290882B2 (en) | 2006-08-28 | 2013-02-21 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| WO2008026999A2 (en) * | 2006-08-28 | 2008-03-06 | Omnio Healer Ab | Candidates against infection |
| EA033403B1 (ru) * | 2013-08-13 | 2019-10-31 | Sanofi Sa | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| TW201722464A (zh) | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| CA3047171A1 (en) | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating pathological renal tissue injury |
| TW201829448A (zh) * | 2016-12-15 | 2018-08-16 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途 |
| CA3046666A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating tissue and organ fibrosis |
-
2018
- 2018-06-15 TW TW107120839A patent/TW201904990A/zh unknown
- 2018-06-22 SG SG11201912813SA patent/SG11201912813SA/en unknown
- 2018-06-22 ES ES18821458T patent/ES2965937T3/es active Active
- 2018-06-22 US US16/625,335 patent/US11826404B2/en active Active
- 2018-06-22 EP EP18821458.9A patent/EP3641888B1/en active Active
- 2018-06-22 FI FIEP18821458.9T patent/FI3641888T3/fi active
- 2018-06-22 WO PCT/IB2018/000655 patent/WO2018234861A1/en active Application Filing
- 2018-06-22 BR BR112019027229-1A patent/BR112019027229A2/pt not_active Application Discontinuation
- 2018-06-22 CA CA3068153A patent/CA3068153A1/en active Pending
- 2018-06-22 DK DK18821458.9T patent/DK3641888T3/da active
- 2018-06-22 JP JP2019570806A patent/JP2020524689A/ja active Pending
- 2018-06-22 AU AU2018287316A patent/AU2018287316A1/en active Pending
- 2018-06-22 MX MX2019015741A patent/MX2019015741A/es unknown
- 2018-06-22 KR KR1020207001617A patent/KR20200019217A/ko unknown
- 2018-06-22 RU RU2020100080A patent/RU2020100080A/ru unknown
- 2018-06-22 CN CN201880041573.5A patent/CN110831668B/zh active Active
-
2019
- 2019-12-16 IL IL271470A patent/IL271470A/en unknown
- 2019-12-20 CL CL2019003789A patent/CL2019003789A1/es unknown
-
2020
- 2020-01-15 ZA ZA2020/00280A patent/ZA202000280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202000280B (en) | 2021-08-25 |
| CL2019003789A1 (es) | 2020-07-10 |
| CN110831668A (zh) | 2020-02-21 |
| JP2020524689A (ja) | 2020-08-20 |
| KR20200019217A (ko) | 2020-02-21 |
| ES2965937T3 (es) | 2024-04-17 |
| EP3641888B1 (en) | 2023-10-11 |
| CA3068153A1 (en) | 2018-12-27 |
| EP3641888A1 (en) | 2020-04-29 |
| EP3641888A4 (en) | 2021-03-10 |
| MX2019015741A (es) | 2020-11-11 |
| US11826404B2 (en) | 2023-11-28 |
| RU2020100080A3 (ru) | 2021-11-02 |
| DK3641888T3 (da) | 2024-01-02 |
| AU2018287316A1 (en) | 2020-02-06 |
| US20210330761A1 (en) | 2021-10-28 |
| TW201904990A (zh) | 2019-02-01 |
| RU2020100080A (ru) | 2021-07-23 |
| BR112019027229A2 (pt) | 2020-07-07 |
| FI3641888T3 (fi) | 2023-12-19 |
| WO2018234861A1 (en) | 2018-12-27 |
| IL271470A (en) | 2020-01-30 |
| CN110831668B (zh) | 2024-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| ZA202000280B (en) | Plasminogen treatment of conditions associated with pai-1 overexpression | |
| ZA202006746B (en) | Methods of treatment | |
| IL271085A (en) | Bacteria to treat disorders | |
| IL261959B1 (en) | Cancer treatment with tg02 | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| IL268694A (en) | Treatment of schizophrenia | |
| PT3297628T (pt) | Azasetron para uso no tratamento de perda auditiva | |
| ZA201907401B (en) | Treatment of adipocytes | |
| PT3122349T (pt) | Composições para o tratamento da autodigestão | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| HK1255695A1 (zh) | 用於治療眼瞼下垂的組合物和方法 | |
| GB201614415D0 (en) | Enzymes for the treatment of human enterometabolic dysfunction | |
| HUE053089T2 (hu) | Migrén kezelése acetil-leucinnal | |
| IL274748A (en) | Improved cancer treatment | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| HK1252359A1 (zh) | 用於治療疼痛的曲唑酮和加巴噴丁的組合 | |
| LT3781172T (lt) | Pneumonijos gydymas | |
| GB201721278D0 (en) | Compunds and combinations for the treatment of rosacea | |
| HK1250343A1 (zh) | 用於治療聽力損失的司瓊類鈣調神經磷酸酶抑制劑 | |
| GB201706817D0 (en) | Treatment of migraines | |
| GB201704287D0 (en) | Treatment of cancer | |
| GB201703857D0 (en) | Treatment of cancer | |
| GB201702565D0 (en) | Treatment of cancer | |
| SG10201913141UA (en) | Treatment of alphavirus-induced inflammation |